A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
ImmunoGen, Inc.
Start Date
December 30, 2024
End Date
October 31, 2029
Administered By
Duke Cancer Institute
Awarded By
ImmunoGen, Inc.
Start Date
December 30, 2024
End Date
October 31, 2029